CYP2C8

Cytochroma P450 CYP2C8 (-atis, n.) (Numerus EC: 1.14.14.1) est haemoproteinum oxidoreductasisque et pars gregis cytochromatum P450.

Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.

Natura structuraque biochemica

Cytochroma P450 CYP2C8 abunde in iecore reperiuntur^[1]. CYP2C8 est et polypeptidum et haemoproteinum, quod ex 476 acidis aminicis constitutum est. Plus quam 100 medicamenta substrata nota sunt. Nonnullae substantiae etiam, ut Gemfibrozilum vel Clopidogrelum, gravissime CYP2C8 inhibere possunt.

Genetica

Nomen geni cytochromatis est CYP2C8 locus cuius geneticus in chromosomate 10 humano locatus est (cytogeneticus: 10q23.33 / coordinatae genomicae: chr10:96,796,884-96,829,159)^[2]. Varia allela descripta sunt (CYP2C8*2, CYP2C8*3, CYP2C8*4, CYP2C8*5)^[3]^[4]. Plus quam 20 singularis nucleotidi polymorphismorum (SNP) notae sunt^[5]:

Polyphormismus	Locus nucleotidi	Nota
Polymorphismi CYP2C8
CYP2C8*2	I269F
CYP2C8*3	R139K
	K399R
	G416A
	A1196G
CYP2C8*4	I264M
CYP2C8*5	T130N
	E154D
	N193K
	K249R
	L390S
	P404A
	H411L

Pharmaca ad CYP2C8 relata

Adhuc solum Rifampicinum inductor notum est.

Substrati	Inhibitores^[8]	Inductores^[9]
Pharmaca relata ad CYP2C8^[6]^[7].
Chemotherapeutica contra malariam Amodiaquinum Chloroquinum Antidiabetica Repaglinidum Rosiglitazonum Analgetica Diclophenac Ibuprofenum Buprenorphinum Inhibitor CSE Cerivastatinum Dasabuvirum Enzalutamidum Loperamidum Montelukastum Paclitaxelum^[10] Sorafenibum Torasemidum	Antibiotica Cotrimoxazolum Trimethoprimum Clopidogrelum (forte) Deferasiroxum Gemfibrozilum (forte) Leflunomidum Montelukastum Teriflunomidum Lapatinibum Quercetinum	Antibiotica Rifampicinum

Notae

↑ Backman J. T., Filppula A. M., Niemi M., Neuvonen P. J. (2016). "Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions". Pharmacol Rev 68 (1): 168-241
↑ [https://web.archive.org/web/20170528092617/http://www.rcsb.org/pdb/gene/CYP2C8 PDB proteinorum collegium datis (Protein Data Bank)
↑ Wu X., Zuo J., Guo T., Yuan L. (2013). "CYP2C8 polymorphism frequencies among Han, Uighur, Hui, and Mongolian Chinese populations". Genet Test Mol Biomarkers 17 (2): 104-8
↑ Nakajima M., Fujiki Y., Noda K., Ohtsuka H., Ohkuni H., Kyo S., Inoue M., Kuroiwa Y., Yokoi T. (2003). "Genetic polymorphisms of CYP2C8 in Japanese population". Drug Metab Dispos 31 (6): 687-90
↑ Pechandova K., Buzkova H., Matouskova O., Perlik F., Slanar O. (2012). "Genetic polymorphisms of CYP2C8 in the Czech Republic". Genet Test Mol Biomarkers 16 (7): 812-6
↑ Cozza KL, Armstrong SC (2001). The Cytochrome P450 System. Drug Interaction Principles for Medical Practice. Washington, DC: American Psychiatric Publishing
↑ Preskorn SH (1996). Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. 1st ed.: Professional Communications, Inc.
↑ Inhibitor cum subtratorum effectibus fortioribus
↑ Inductor cum subtratorum effectibus minoribus
↑ Rodríguez-Antona C. (2010). "Pharmacogenomics of paclitaxel". Pharmacogenomics 11 (5): 621-3

Nexus externi

Descriptio genetica CYP2C8: https://web.archive.org/web/20200928164956/https://ghr.nlm.nih.gov/gene/CYP2C8

[1] Backman J. T., Filppula A. M., Niemi M., Neuvonen P. J. (2016). "Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions". Pharmacol Rev 68 (1): 168-241

[2] [https://web.archive.org/web/20170528092617/http://www.rcsb.org/pdb/gene/CYP2C8 PDB proteinorum collegium datis (Protein Data Bank)

[3] Wu X., Zuo J., Guo T., Yuan L. (2013). "CYP2C8 polymorphism frequencies among Han, Uighur, Hui, and Mongolian Chinese populations". Genet Test Mol Biomarkers 17 (2): 104-8

[4] Nakajima M., Fujiki Y., Noda K., Ohtsuka H., Ohkuni H., Kyo S., Inoue M., Kuroiwa Y., Yokoi T. (2003). "Genetic polymorphisms of CYP2C8 in Japanese population". Drug Metab Dispos 31 (6): 687-90

[5] Pechandova K., Buzkova H., Matouskova O., Perlik F., Slanar O. (2012). "Genetic polymorphisms of CYP2C8 in the Czech Republic". Genet Test Mol Biomarkers 16 (7): 812-6

[6] Cozza KL, Armstrong SC (2001). The Cytochrome P450 System. Drug Interaction Principles for Medical Practice. Washington, DC: American Psychiatric Publishing

[7] Preskorn SH (1996). Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. 1st ed.: Professional Communications, Inc.

[8] Inhibitor cum subtratorum effectibus fortioribus

[9] Inductor cum subtratorum effectibus minoribus

[10] Rodríguez-Antona C. (2010). "Pharmacogenomics of paclitaxel". Pharmacogenomics 11 (5): 621-3

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]